Skip to content

Zevra Therapeutics, Inc. ZVRA Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$124.22M+49.2%$83.23M+136%$35.33M+1,236%$2.64M+103%-$91.99M+12.8%
$2.77M-31.6%$4.05M-24.1%$5.34M-18.7%$6.57M+1.4%$6.48M+1.4%
$12.62M-0.1%$12.63M+2.2%$12.37M-21.4%$15.73M-1.1%$15.9M+6.7%
-$46.21M+25.1%-$61.72M+11.4%
$802K-7.4%$866K0.0%$866K+178%$312K+215%$99K
-$14.35M+45.7%-$26.41M-19.2%
$60.09M$0
-$42.35M-451%$12.06M+17.0%$10.31M-85.0%$68.55M-16.9%$82.5M+0.5%
$58.26M+104%$28.62M+7,055%$400K-95.3%$8.45M+253%-$5.51M+40.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Zevra Therapeutics, Inc. generate?
Zevra Therapeutics, Inc. (ZVRA) generated -$21.9M in operating cash flow over the trailing twelve months.
What is Zevra Therapeutics, Inc.'s free cash flow?
After $802.0K of capital expenditures, Zevra Therapeutics, Inc.'s free cash flow was -$22.3M over the trailing twelve months, up 68.0% year over year.
Where does Zevra Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.